Total Payments
$9,876
2024 Payments
$1,894
Companies
18
Transactions
160
Payment Breakdown by Category
Research$5,379 (54.5%)
Food & Beverage$3,728 (37.7%)
Travel$498.90 (5.1%)
Consulting$150.00 (1.5%)
Education$120.15 (1.2%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5,379 | 19 | 54.5% |
| Food and Beverage | $3,728 | 135 | 37.7% |
| Travel and Lodging | $498.90 | 2 | 5.1% |
| Consulting Fee | $150.00 | 1 | 1.5% |
| Education | $120.15 | 3 | 1.2% |
Payments by Type
Research
$5,379
19 transactions
General
$4,497
141 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $3,159 | 57 | $0 (2024) |
| Eli Lilly Export S.A. Puerto Rico Branch | $3,025 | 2 | $0 (2024) |
| Eli Lilly and Company | $1,612 | 6 | $0 (2019) |
| Janssen Pharmaceuticals, Inc | $752.44 | 63 | $0 (2024) |
| PBG PUERTO RICO LLC | $238.11 | 7 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $205.81 | 6 | $0 (2023) |
| Biogen, Inc. | $150.00 | 1 | $0 (2019) |
| Janssen Scientific Affairs, LLC | $107.67 | 1 | $0 (2017) |
| Janssen Biotech, Inc. | $99.00 | 1 | $0 (2020) |
| Boston Scientific Corporation | $98.79 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,894 | 27 | ABBVIE INC. ($1,748) |
| 2023 | $701.82 | 19 | AbbVie Inc. ($448.79) |
| 2022 | $321.38 | 11 | PBG PUERTO RICO LLC ($111.22) |
| 2021 | $17.27 | 1 | Organon LLC ($17.27) |
| 2020 | $166.83 | 4 | Janssen Biotech, Inc. ($99.00) |
| 2019 | $1,983 | 27 | Eli Lilly and Company ($953.21) |
| 2018 | $4,165 | 38 | Eli Lilly Export S.A. Puerto Rico Branch ($3,000) |
| 2017 | $626.70 | 33 | Janssen Pharmaceuticals, Inc ($243.80) |
All Payment Transactions
160 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Eli Lilly Export S.A. Puerto Rico Branch | OMVOH (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: Immunology | ||||||
| 10/24/2024 | Janssen Pharmaceuticals, Inc | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $34.75 | General |
| Category: Immunology | ||||||
| 10/09/2024 | Janssen Pharmaceuticals, Inc | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $28.83 | General |
| Category: Immunology | ||||||
| 09/26/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: VIROLOGY | ||||||
| 09/26/2024 | Janssen Pharmaceuticals, Inc | STELARA (Biological) | Food and Beverage | In-kind items and services | $13.76 | General |
| Category: Immunology | ||||||
| 09/18/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $29.59 | General |
| Category: IMMUNOLOGY | ||||||
| 07/15/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $30.00 | General |
| 07/15/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $25.00 | General |
| 06/13/2024 | PBG PUERTO RICO LLC | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $18.55 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 05/20/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $10.38 | General |
| 05/09/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: VIROLOGY | ||||||
| 04/20/2024 | ABBVIE INC. | — | — | In-kind items and services | $45.75 | Research |
| Study: A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Risankizumab Subcutaneous Induction Treatment in Subjects With Moderately to Severely Active Crohn's Disease | ||||||
| 04/20/2024 | ABBVIE INC. | — | — | In-kind items and services | $7.60 | Research |
| Study: A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Risankizumab Subcutaneous Induction Treatment in Subjects With Moderately to Severely Active Crohn's Disease | ||||||
| 04/19/2024 | ABBVIE INC. | SKYRIZI (Biological) | — | In-kind items and services | $438.60 | Research |
| Study: A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Risankizumab Subcutaneous Induction Treatment in Subjects With Moderately to Severely Active Crohn's Disease • Category: IMMUNOLOGY | ||||||
| 04/19/2024 | ABBVIE INC. | SKYRIZI (Biological) | — | In-kind items and services | $106.43 | Research |
| Study: A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Risankizumab Subcutaneous Induction Treatment in Subjects With Moderately to Severely Active Crohn's Disease • Category: IMMUNOLOGY | ||||||
| 04/19/2024 | ABBVIE INC. | SKYRIZI (Biological) | — | In-kind items and services | $69.99 | Research |
| Study: A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Risankizumab Subcutaneous Induction Treatment in Subjects With Moderately to Severely Active Crohn's Disease • Category: IMMUNOLOGY | ||||||
| 04/19/2024 | ABBVIE INC. | SKYRIZI (Biological) | — | In-kind items and services | $59.99 | Research |
| Study: A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Risankizumab Subcutaneous Induction Treatment in Subjects With Moderately to Severely Active Crohn's Disease • Category: IMMUNOLOGY | ||||||
| 04/19/2024 | ABBVIE INC. | SKYRIZI (Biological) | — | In-kind items and services | $33.48 | Research |
| Study: A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Risankizumab Subcutaneous Induction Treatment in Subjects With Moderately to Severely Active Crohn's Disease • Category: IMMUNOLOGY | ||||||
| 04/19/2024 | ABBVIE INC. | SKYRIZI (Biological) | — | In-kind items and services | $31.77 | Research |
| Study: A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Risankizumab Subcutaneous Induction Treatment in Subjects With Moderately to Severely Active Crohn's Disease • Category: IMMUNOLOGY | ||||||
| 04/18/2024 | ABBVIE INC. | SKYRIZI (Biological) | — | In-kind items and services | $366.76 | Research |
| Study: A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Risankizumab Subcutaneous Induction Treatment in Subjects With Moderately to Severely Active Crohn's Disease • Category: IMMUNOLOGY | ||||||
| 04/18/2024 | ABBVIE INC. | SKYRIZI (Biological) | — | In-kind items and services | $210.88 | Research |
| Study: A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Risankizumab Subcutaneous Induction Treatment in Subjects With Moderately to Severely Active Crohn's Disease • Category: IMMUNOLOGY | ||||||
| 04/18/2024 | ABBVIE INC. | SKYRIZI (Biological) | — | In-kind items and services | $152.66 | Research |
| Study: A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Risankizumab Subcutaneous Induction Treatment in Subjects With Moderately to Severely Active Crohn's Disease • Category: IMMUNOLOGY | ||||||
| 04/18/2024 | ABBVIE INC. | — | — | In-kind items and services | $27.50 | Research |
| Study: A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. (AFFIRM) | ||||||
| 04/18/2024 | ABBVIE INC. | — | — | In-kind items and services | $13.19 | Research |
| Study: A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. (AFFIRM) | ||||||
| 04/18/2024 | ABBVIE INC. | — | — | In-kind items and services | $12.06 | Research |
| Study: A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Risankizumab Subcutaneous Induction Treatment in Subjects With Moderately to Severely Active Crohn's Disease | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF BARICITINIB (LY3009104) IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS WHO HAVE AN INADEQUATE RESPONSE OR ARE INTOLERANT TO UDCA | Eli Lilly Export S.A. Puerto Rico Branch | $3,000 | 1 |
| A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Risankizumab Subcutaneous Induction Treatment in Subjects With Moderately to Severely Active Crohn's Disease | ABBVIE INC. | $1,536 | 12 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF BARICITINIB (LY3009104) IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS WHO HAVE AN INADEQUATE RESPONSE OR ARE INTOLERANT TO UDCA | Eli Lilly and Company | $713.42 | 2 |
| Adult Allogeneic Expanded Adipose-derived Stem Cells eASC for the Treatment of Complex Perianal Fistulas in Patients With Crohn's Disease ADMIRE-CD-II | Takeda Pharmaceuticals U.S.A., Inc. | $89.22 | 2 |
| A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. (AFFIRM) | ABBVIE INC. | $40.69 | 2 |
About Dr. Esther Torres, M.D
Dr. Esther Torres, M.D is a Gastroenterology healthcare provider based in San Juan, Puerto Rico. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/22/2005. The National Provider Identifier (NPI) number assigned to this provider is 1871576900.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Esther Torres, M.D has received a total of $9,876 in payments from pharmaceutical and medical device companies, with $1,894 received in 2024. These payments were reported across 160 transactions from 18 companies. The most common payment nature is "" ($5,379).
Ad
Practice Information
- Specialty Gastroenterology
- Location San Juan, PR
- Active Since 11/22/2005
- Last Updated 05/28/2015
- Taxonomy Code 207RG0100X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1871576900
Products in Payments
- SKYRIZI (Biological) $1,623
- STELARA (Biological) $643.73
- Humira (Biological) $415.25
- RINVOQ (Biological) $306.56
- Mavyret (Drug) $287.51
- ZYTIGA (Drug) $207.98
- MAVYRET (Drug) $150.00
- TYSABRI (Biological) $150.00
- Entyvio (Biological) $103.51
- ORISE (Device) $98.79
- RENFLEXIS (Biological) $98.04
- ENTYVIO (Biological) $91.59
- INFLECTRA (Biological) $76.13
- ZEPOSIA (Drug) $68.30
- TREMFYA (Drug) $63.58
- XELJANZ (Drug) $54.62
- XARELTO (Drug) $43.82
- HUMIRA (Biological) $29.93
- OMVOH (Drug) $25.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in San Juan
Dr. Henry Gonzalez-Rivera, M.d, M.D
Gastroenterology — Payments: $39,430
Gastroenterology $39,430
Hector Lozano, Md, MD
Gastroenterology — Payments: $38,375
Gastroenterology $38,375
Dr. Rafael Rodriguez - Lopez, Md, MD
Gastroenterology — Payments: $20,525
Gastroenterology $20,525
Yahaira Moreno Denizard, M.d, M.D
Gastroenterology — Payments: $14,726
Gastroenterology $14,726
Dr. Emmanuel Reyes-Ramos, M.d, M.D
Gastroenterology — Payments: $7,845
Gastroenterology $7,845
Fernando Ramos-Mercado, Md, MD
Gastroenterology — Payments: $7,660
Gastroenterology $7,660